Overview
IART market data
Price History
IART price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$6.74 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.21 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.70 – $20.26 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.5K · P/B 0.93 · P/S 0.89.
Company news
Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19Benzinga · Jul 16, 2026, 4:10 PM
BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19Benzinga · Jul 9, 2026, 3:01 PM
Citigroup Maintains Neutral on Integra Lifesciences, Raises Price Target to $19Benzinga · Jul 8, 2026, 3:45 PM
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItBenzinga · May 22, 2026, 3:15 PM
8-K filing — INTEGRA LIFESCIENCES HOLDINGS CORP (IART)SEC EDGAR · May 8, 2026, 8:15 PM
Integra LifeSciences Reports First Quarter 2026 Financial ResultsGlobenewswire Inc · May 5, 2026, 10:05 AM